EX4 stabilizes and activates Nrf2 via PKCδ, contributing to the prevention of oxidative stress-induced pancreatic beta cell damage.
Toxicol Appl Pharmacol · 2017
Last updated 2026-05-28In lab tests on rat insulin-producing cells, a GLP-1 drug called exendin-4 (EX4) reduced harmful oxygen molecules, restored protective glutathione levels, and improved insulin release when the cells faced oxidative stress. EX4 also boosted the activity of antioxidant genes and helped stabilize a key protein called Nrf2, which in turn supported cell function. Blocking a specific signaling pathway (PKCδ) weakened these protective effects.
AI summary of the abstract below.
| Journal | Toxicol Appl Pharmacol, 2017 |
|---|---|
| Citations | 50 |
| Relative citation ratio | 2.24 |
| NIH percentile | 77 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Oxidative stress in pancreatic beta cells can inhibit insulin secretion and promote apoptotic cell death. Exendin-4 (EX4), a glucagon-like peptide-1 receptor agonist, can suppress beta cell apoptosis, improve beta cell function and protect against oxidative damage. In this study, we investigated the molecular mechanisms for antioxidative effects of EX4 in pancreatic beta cells. INS-1 cells, a rat insulinoma cell line, were pretreated with EX4 and exposed to palmitate or HO. Reactive oxygen species (ROS) production, and glutathione and insulin secretion were measured. The mRNA and protein expression levels of antioxidant genes were examined. The level of nuclear factor erythroid 2-related factor 2 (Nrf2), its binding to antioxidant response element (ARE), and its ubiquination in the presence of EX4 were determined. The Nrf2 signaling pathway was determined using rottlerin (protein kinase [PK]Cδ inhibitor), H89 (PKA inhibitor) and LY294002 (phosphatidylinositide 3-kinase [PI3K] inhibitor). EX4 treatment decreased ROS production, recovered cellular glutathione levels and insulin secretion in the presence of oxidative stress in INS-1 cells. The expression levels of glutamate-cysteine ligase catalytic subunit and heme oxygenase-1 were increased by EX4 treatment. EX4 promoted Nrf2 translocation, ARE binding activity and enhanced stabilization of Nrf2 by inhibition of ubiquitination. Knockdown of Nrf2 abolished the effect of EX4 on increased insulin secretion. Inhibition of PKCδ attenuated Nrf2 translocation and antioxidative gene expression by EX4 treatment. We suggest that EX4 activates and stabilizes Nrf2 through PKCδ activation, contributing to the increase of antioxidant gene expression and consequently improving beta cell function in the presence of oxidative stress.
Verbatim abstract via PubMed 27939242 ↗